Paper I — 2024 December (Supplementary) (2019 Scheme) — Qxviii
2 min read
Paper I
2024 December (Supplementary) (2019 Scheme) · 100 marks · 180 min
Question
Assertion (A): Lignocaine is one of the preferred drugs in paroxysmal supraventricular tachycardia.
Reason (R): Lignocaine is a blocker of inactivated Na+ channels more than that of open state. It is relatively selective for partially depolarized cells and those with longer action potential duration.
Tap an option to answer
Qxviii1 marksMCQs
Answer
Correct answer: d) A is false, but R is true
A is false — lignocaine is a Class IB antiarrhythmic used for ventricular arrhythmias (particularly post-myocardial infarction), not paroxysmal supraventricular tachycardia. R is a true, accurate description of lignocaine’s mechanism: it preferentially blocks inactivated Na⁺ channels, giving it selectivity for partially depolarized (ischemic) tissue and cells with longer action potential duration — this mechanism explains its ventricular-arrhythmia selectivity, not an SVT indication.